Drug Trial Radar · NCT02541955
Use of Acthar in Rheumatoid Arthritis (RA) Related Flares
Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jul 20, 2017
Primary completion
May 6, 2025
Study completion May 20, 2025
Sponsor
- Lead sponsor
- Veena Ranganath, MD, MSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mallinckrodt
- First posted
- Sep 4, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Rheumatoid Arthritis (RA) study. The purpose of this research study is to determine in RA flare, whether musculoskeletal ultrasound (MSUS) inflammatory scores and/or disease activity scores improve with Acthar treatment.
Conditions
- Rheumatoid Arthritis (RA)
Interventions
ActharDrug
Injections will be self administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- DAS28Time frame: Baseline to 4 Weeks
- Power Doppler Ultrasound ScoreTime frame: Baseline to 4 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UCLA David Geffen School of Medicine, Division of Rheumatology
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.